Microenvironment and Immunology Immunosurveillance by Antiangiogenesis : Tumor Growth Arrest by T Cell – Derived Thrombospondin-1
暂无分享,去创建一个
E. Wherry | L. Braunstein | S. Ryeom | Jill M. Angelosanto | Alison Crawford | Kwan-Hyuck Baek | Keri L Schadler | A. Zhou | D. Bhang | Erika J. Crosby | D. Crawford
[1] E John Wherry,et al. Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. , 2012, Immunity.
[2] S. Gregory,et al. Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C , 2012, Virulence.
[3] J. Henkin,et al. Prospective study of thrombospondin-1 mimetic peptides, ABT-510 and ABT-898, in dogs with soft tissue sarcoma. , 2012, Journal of veterinary internal medicine.
[4] Jacob K. White,et al. Plasmin triggers a switch-like decrease in thrombospondin-dependent activation of TGF-β1. , 2012, Biophysical journal.
[5] Ruchi Bansal,et al. Selective Targeting of Interferon γ to Stromal Fibroblasts and Pericytes as a Novel Therapeutic Approach to Inhibit Angiogenesis and Tumor Growth , 2012, Molecular Cancer Therapeutics.
[6] J. Lawler,et al. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. , 2012, Cold Spring Harbor perspectives in medicine.
[7] A. Carbone,et al. Cancers related to viral agents that have a direct role in carcinogenesis: pathological and diagnostic techniques , 2012, Journal of Clinical Pathology.
[8] Steven A. Rosenberg,et al. Raising the Bar: The Curative Potential of Human Cancer Immunotherapy , 2012, Science Translational Medicine.
[9] J. Harford. Viral infections and human cancers: the legacy of Denis Burkitt , 2012, British journal of haematology.
[10] S. Rosenberg,et al. Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice , 2012, Clinical Cancer Research.
[11] G. Semenza,et al. Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1 , 2011, Cell.
[12] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.
[13] Lin Zhang,et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells , 2011, Nature.
[14] A. J. Mixson,et al. Vaccines targeting the neovasculature of tumors , 2011, Vascular cell.
[15] D. Roberts,et al. Heparan Sulfate Modification of the Transmembrane Receptor CD47 Is Necessary for Inhibition of T Cell Receptor Signaling by Thrombospondin-1* , 2011, The Journal of Biological Chemistry.
[16] E. Tartour,et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy , 2011, Cancer and Metastasis Reviews.
[17] C. Loddenkemper,et al. Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis , 2011, International journal of cancer.
[18] Kavya Rakhra,et al. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. , 2010, Cancer cell.
[19] S. Rosenberg,et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. , 2010, The Journal of clinical investigation.
[20] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[21] H. Fathallah-Shaykh,et al. A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. , 2010, Archives of Neurology.
[22] Y. Liu,et al. A promising new approach of VEGFR2-based DNA vaccine for tumor immunotherapy. , 2009, Immunology letters.
[23] I. De Meester,et al. A CD26-Controlled Cell Surface Cascade for Regulation of T Cell Motility and Chemokine Signals1 , 2009, The Journal of Immunology.
[24] Yuzhang Wu,et al. DNA Vaccine Against Tumor Endothelial Marker 8 Inhibits Tumor Angiogenesis and Growth , 2009, Journal of immunotherapy.
[25] M. Linial,et al. Apoptotic cell thrombospondin-1 and heparin-binding domain lead to dendritic-cell phagocytic and tolerizing states. , 2006, Blood.
[26] Hao Shen,et al. An Essential Role of Th1 Responses and Interferon-gamma in Infection-Mediated Suppression of Neoplastic Growth , 2003, Cancer biology & therapy.
[27] J. Lawler,et al. Thrombospondin‐1 as an endogenous inhibitor of angiogenesis and tumor growth , 2002, Journal of cellular and molecular medicine.
[28] C. Hunter,et al. Cutting Edge: Systemic Inhibition of Angiogenesis Underlies Resistance to Tumors During Acute Toxoplasmosis1 , 2001, The Journal of Immunology.
[29] N. Ahuja,et al. Methylation and silencing of the Thrombospondin-1 promoter in human cancer , 1999, Oncogene.
[30] R. Hynes,et al. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. , 1998, The Journal of clinical investigation.
[31] S. Groshen,et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. , 1997, Journal of the National Cancer Institute.
[32] H. Pircher,et al. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. , 2003, Cancer research.
[33] G. Beatty,et al. IFN-g Can Promote Tumor Evasion of the Immune System In Vivo by Down-Regulating Cellular Levels of an Endogenous Tumor Antigen , 2000 .